Furthermore, the use of inhibitors has shown that metalloproteinases secretion and proliferation of breast cancer cells relies on EGFR transactivation and activation of the EGFR/ERK1/2 MAPK cascade (6, 28). This evidence concerns the gene EGFR and breast carcinoma.